Final FDA Guidance: What Constitutes a Delayed or Refused Drug Inspection?
FDA final guidance detailing the types of actions, inaction, and circumstances that the FDA considers to constitute delaying, denying, or limiting inspection, or refusing to permit entry or inspection.
Health Care Reveals its Supply Chain Pain
Significant factors contributing to uncertainty in the healthcare supply chain are more stringent regulations and increased product protection challenges
Supply Chain Security Breaches Increase Regulatory Scrutiny, Says Dow Corning
OEMs must comply with additional regulatory requirements
All-Star Innovators 2014
Pharma’s tech bench gets deeper with an All-Star lineup ready for the big leagues